References
- A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918
- Horning S J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75–88
- Horning S J. Follicular lymphoma: have we made any progress?. Ann Oncol 2000; 11(Suppl 1)23–27
- Swenson W T, Wooldridge J E, Lynch C F, Forman-Hoffman V L, Chrischilles E, Link B K. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23: 5019–5026
- Taylor P RA, White J M, Prescott R J, et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodkgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leuk Lymph 2006; 47(11)2321–2330
- Baldini L, Brugiatelli M, Luminari S, Lombardo M, Merli F, Sacchi S, , et al. Treatment of indolent B-cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. J Clin Oncol 2003; 21: 1459–1465
- Rigacci L, Federico M, Martelli M, et al. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma 2003; 44: 1911–1917
- Czuczman M S, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694–704
- Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Front-line therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone – results of a prospective randomized study of the german low grade lymphoma study group (GLSG). Blood 2005; 106: 3725–3732
- Mc Laughlin P, Rodriguez M A, Hagemeister F, Romaguera J E, Sarris A, Younes A, et al (2005) Stage IV indolent Lymphoma: a randomized trial of concurrent vs. sequential FND (fludarabine, mitoxantrone, dexamethasone) and rituximab, with interferon maintenance. Ninth ICML. June, 8 – 112005. ICML, Lugano
- Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423